Drug Profile
18F flurpiridaz F 18 - GE Healthcare/Lantheus Medical Imaging
Alternative Names: 18F-flurpiridaz; BMS-747158; BMS-747158-02; Flurpiridaz (18F) InjectionLatest Information Update: 09 Oct 2023
Price :
$50
*
At a glance
- Originator Lantheus Medical Imaging
- Developer GE Healthcare; Lantheus Medical Imaging
- Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Coronary artery disease
Most Recent Events
- 25 Aug 2023 Efficacy data from a phase III AURORA trial in Coronary artery disease presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology (ESC-Card-2023)
- 13 Sep 2022 Efficacy data from a phase III trial in Coronary artery disease released by GE Healthcare
- 13 Jun 2022 Lantheus Medical Imaging expects regulatory approval of Flurpiridaz F-18 for Coronary artery disease in early 2024 (Lantheus Medical Imaging pipeline, June 2022)